The Hang Seng Index closed up 0.13%, and the Hang Seng Tech Index rose 0.11%. Meituan increased by nearly 6%, Hengrui Pharma rose by nearly 5%, GDS surged over 3%, and JD.com rose over 2%

Morning Trend | HENGRUI PHARMA (1276.HK) faces pressure with reduced volume, is the sector rotation about to change?

HENGRUI PHARMA (1276.HK) showed significant sensitivity in capital flow after the market closed yesterday, with trading volume remaining sluggish throughout the day and a lack of obvious buying pressure. The stock continued to oscillate weakly below the short-term moving averages. The main funds maintained a wait-and-see trend, with short-term trading activity noticeably declining, and large funds primarily adopting a defensive posture. Recently, the A-share pharmaceutical sector has been under overall pressure, influenced by policy signals such as "drug price negotiations" and "adjustments to the medical insurance catalog." As an industry leader, HENGRUI's market expectations continue to be suppressed. Institutional investors are hesitant to bottom-fish, and retail investors are also showing obvious caution, further amplifying the wait-and-see atmosphere in the market. From a technical perspective, the daily MACD has just formed a death cross, and the moving averages are in a bearish arrangement, putting overall pressure on the market. Intraday, right-side traders are more inclined to control their exposure, resulting in a cautious overall atmosphere. From the market's viewpoint, if there are positive changes in policies or at the industry or company level, there may still be a window for recovery in the sector. However, at this stage, it is crucial to focus on previous lows and related policy dynamics. If key support is breached, there is a risk of further inertia downward in the stock price. In the short term, it is essential to closely monitor intraday volume, industry policies, and sector rotation signals to guard against sudden risks

Hengrui Pharma's SHR-1139 injection has been approved to conduct clinical trials

Hengrui Pharma announced that its subsidiary Guangdong Hengrui received a notification from the National Medical Products Administration, approving SHR-1139 injection to conduct clinical trials for pyoderma gangrenosum. To date, the cumulative R&D investment for the HR-1139 injection-related project is approximately 100 million RMB

S&P Global Market Intelligence lists the top ten shorted Hong Kong stocks recently

S&P Global Market Intelligence listed the top ten shorted stocks in Hong Kong as of November 14, based on securities financing data. Hengrui Pharma, Vanke, CATL, and other companies were identified as stocks with a high short interest

Hengrui Pharma's Zhang Lianshan: The gap in R&D levels between domestic pharmaceutical companies and foreign ones is rapidly narrowing

Zhang Lianshan, Global R&D President of Hengrui Pharma, stated at the International Investors Conference of the Shanghai Stock Exchange that the company's practices in new molecular design over the past 20 years have proven its innovation capabilities. In the future, the company will upgrade from quantity to higher quality, building a foundation and channels for the international market